יתרות מזומנים למניה אחת achillestx.com (ACHL)

Achilles Therapeutics (ACHL) is developing unique methods for combating solid tumors through partnerships with oncology centers. An analysis of cash per share shows that the value of this metric is 2.10. Liquidity is supported by the sector's independence from macroeconomics, although product scaling relies on external contract manufacturers and strict international compliance.
פילוחי מדדים מקיפים ואנליטיקה עבור achillestx.com (ACHL)

This indicator determines the intrinsic value of an asset through the lens of liquidity. By analyzing the cash per share, an investor assesses the company's actual cash cushion. The metric is calculated by dividing the total amount of cash and cash equivalents by the number of shares outstanding. This metric confirms the financial stability of Achilles Therapeutics (ACHL). Maintaining proprietary sterile facilities in the UK requires constant capital to ensure operational stability.